2-Methoxy-5-(2-(3,4,5-trimethoxyphenyl)thiophen-3-yl)
aniline (DAT-230) is a novel synthesized compound of combretastatin-A-4 derivative with more stability. The present study is to investigate its anti-
tumor activity and molecular mechanisms in human gastric
adenocarcinoma SGC-7901 cells.
DAT-230 inhibited SGC-7901 cells growth. The treatment of
DAT-230 resulted in microtubule de-polymerization and G2/M phase arrest. Besides the accumulation and translocation of
Cyclin B1, reduction of p-14/15-cdc2 and mitosis delay denoted the
Cyclin B1-cdc2 complex active and M phase arrest in SGC-7901 cells treated with
DAT-230. Mitochondria pathway participated in apoptosis after G2/M arrest in SGC-7901 cells treated with
DAT-230, which was characterized by DNA fragmentation, cleavage of
poly(ADP-ribose) polymerase (PARP), activation of
caspase-3 and
caspase-9, changes of Bcl-2 and Bax expression, decrease of mitochondrial membrane potential and release of
cytochrome c from mitochondria. In vivo,
DAT-230 delayed
tumor growth in BALB/c nude mice with human gastric
adenocarcinoma xenografts. Besides apoptosis was detected with
terminal deoxynucleotidyl transferase mediated
deoxyuridine triphosphate nick-end labeling (TUNEL) assay in
tumor tissue. In conclusion,
DAT-230 is a promising microtubule inhibitor with great anti-
tumor activity to SGC-7901, in vitro and in vivo. Its potential to be a candidate of anti-
cancer agent is worth of being further investigated.